Adolescents Approved for Jynneos Vaccine
The World Health Organisation (WHO) has authorised the use of the Jynneos vaccine, produced by Bavarian Nordic, for adolescents aged 12 to 17. This approval, announced on October 14, 2024, follows the vaccine’s prequalification on October 8 and aims to protect this vulnerable age group from mpox outbreaks. Initially approved for adults, the vaccine’s availability now extends to younger individuals.
EU and U.S. Endorsements Strengthen Global Access
The European Union previously authorised the vaccine for adolescents in September, marking a coordinated global effort to curb the spread of mpox. In parallel, the U.S. Food and Drug Administration (FDA) approved the Jynneos vaccine for adult use. The WHO declared mpox a global public health emergency in August, following the detection of a new strain spreading across multiple countries.
Clinical Trials Planned for Younger Children
Bavarian Nordic is preparing to begin clinical trials to assess the vaccine’s safety and effectiveness for children aged two to 12. The trials are scheduled to commence this month, as health authorities aim to broaden the vaccine’s protective coverage across different age groups.
Alternative Vaccine Approved for Children
In addition to Jynneos, Japan’s KM Biologics developed another mpox vaccine called LC16, which is already authorised for use in children. However, LC16 requires a specialised needle for administration, limiting its widespread application in certain regions.
Mpox Control Remains a Global Priority
The approval of the Jynneos vaccine for adolescents represents a critical step in managing mpox outbreaks. Health experts have emphasised the importance of preventive measures, particularly among younger populations, to limit the spread of the virus and reduce health risks.
International Efforts to Curb Outbreaks
The global response to mpox highlights the urgency of collaboration between countries and health organisations. With vaccination efforts ramping up, authorities remain focused on containing the virus while preparing for potential future outbreaks through continued research and vaccine deployment.
Follow us on Socials:
Twitter
Facebook